* TOTAL : 14,798 건
- Time-in-target range of systolic blood pressure and all-cause mortality in chronic kidney disease population in Korea
-
Soo-Young Yoon2024 ; 2024(1):
- 초록보기 PDF 원문보기
- An Exploratory Trial of an Investigational RNA Therapeutic, IONIS-FB-LRx, for Treatment of IgA Nephropathy: New Interim Results
-
Jason Choo2024 ; 2024(1):
- 초록보기 PDF 원문보기
- Hematuria Resolution with the APRIL-Blocking Monoclonal Antibody, Sibeprenlimab, in Patients with IgA Nephropathy in a Phase 2 Randomized Controlled Trial
-
Muh Geot Wong2024 ; 2024(1):
- 초록보기 PDF 원문보기
- IMAGINATION: A Global Phase 3 Trial of RO7434656, an Antisense Oligonucleotide Inhibitor of Complement Factor B, in IgA Nephropathy
-
Jonathan Barratt2024 ; 2024(1):
- 초록보기 PDF 원문보기
- Humoral Response to COVID Vaccine and Infection is Intact During Sibeprenlimab Treatment of IgAN: Data From the ENVISION Trial
-
Adrian Liew2024 ; 2024(1):
- 초록보기 PDF 원문보기
- Updated Results from the RUBY-3 Study of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoantibody-Associated Glomerulonephritis
-
Jonathan Barratt2024 ; 2024(1):
- 초록보기 PDF 원문보기
- The risk factors for the relapse and aggravation of the patients with primary membranous nephropathy after COVID-19 infection
-
Yue Shu2024 ; 2024(1):
- 초록보기 PDF 원문보기
- Relationship Of Crescents With Clinico-histological Parameters In Lupus Nephritis
-
Uttayan Chakrabarti2024 ; 2024(1):
- 초록보기 PDF 원문보기
- Nogo-B may mediate the glomerular endothelial cell injury of hypertensive nephropathy by enhancing the inflammatory phenotype
-
Shanzhi Yang2024 ; 2024(1):
- 초록보기 PDF 원문보기
(06022) 서울시 강남구 압구정로 30길 23 미승빌딩 301호
- Tel: 02)3486-8736
- Fax: 02)3486-8737
- E-mail: ksn@ksn.or.kr
- 사업자 등록번호: 208-82-60817
- 대표자: 최범순
Copyright© 대한신장학회. All rights reserved.
